Please use this identifier to cite or link to this item:
Title: Determination of thalidomide by high performance liquid chromatography: Plasma pharmacokinetic studies in the rat
Authors: Yang, X.
Hu, Z.
Sui, Y.C.
Ho, P.C.
Chan, E. 
Zhou, S. 
Duan, W. 
Boon, C.G.
Keywords: HPLC
Issue Date: 2005
Source: Yang, X., Hu, Z., Sui, Y.C., Ho, P.C., Chan, E., Zhou, S., Duan, W., Boon, C.G. (2005). Determination of thalidomide by high performance liquid chromatography: Plasma pharmacokinetic studies in the rat. Journal of Pharmaceutical and Biomedical Analysis 39 (1-2) : 299-304. ScholarBank@NUS Repository.
Abstract: A sensitive and simple high performance liquid chromatography (HPLC) method was developed and validated for the determination of thalidomide in rat plasma. Chromatography was accomplished with a reversed-phase Hypersil C18 column. Mobile phase consisted of acetonitrile-10 mM ammonium acetate buffer (pH 5.50) (28:72, v/v), at a flow rate of 0.8 ml/min. Thalidomide was monitored by ultraviolet detector at 220 nm and it gave a linear response as a function of concentration over 0.02-50 μM. The limit of quantitation in rat plasma was 0.50 ng (0.02 μM plasma concentration) with an aliquot of 20 μl. Results from a 3-day validation study indicated that this method allows for simple and rapid quantitation of thalidomide with excellent accuracy and reliability. Using this validated assay, the effect of coadministered irinotecan (CPT-11) on the plasma pharmacokinetics of thalidomide in rats was determined. Coadministration of CPT-11 (intravenously, 60 mg/kg) increased the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC 0-10 h) of thalidomide by 32.29 and 11.66%, respectively, as compared to the control, but none of the effect of CPT-11 was of statistical significance (P > 0.05). Concomitant CPT-11 also caused a 10.04% decrease in plasma clearance (CL) and 14.51% decrease in volume of distribution (V d) (P > 0.05). These results suggest that coadministered CPT-11 did not significantly alter the plasma pharmacokinetics of thalidomide in rats. Further studies are warranted to explore the pharmacokinetic and pharmacodynamic interactions between CPT-11 and thalidomide. © 2005 Elsevier B.V. All rights reserved.
Source Title: Journal of Pharmaceutical and Biomedical Analysis
ISSN: 07317085
DOI: 10.1016/j.jpba.2005.02.041
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Feb 28, 2018


checked on Feb 20, 2018

Page view(s)

checked on Feb 27, 2018

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.